MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. by Ways, D. Kirk et al.
MCF-7 Breast Cancer Cells Transfected with Protein Kinase C-a Exhibit
Altered Expression of Other Protein Kinase C Isoforms and Display a More
Aggressive Neoplastic Phenotype
D. Kirk Ways,* Cynthia A. Kukoly,* James deVente,* Jerry L. Hooker,* Winifred 0. Bryant,* Karla J. Posekany,t
Donald J. Fletcher,* Paul P. Cook,* and Peter J. Parker1l
Departments of *Medicine, WMicrobiology/Immunology, and §Anatomy/Cell Biology, East Carolina University School of Medicine,
Greenville, North Carolina 27858; and 11 Imperial Cancer Research Fund, Protein Phosphorylation Laboratory, London WC2A 3PX,
United Kingdom
Abstract
Increased protein kinase C (PKC) activity in malignant
breast tissue and positive correlations between PKC activity
and expression of a more aggressive phenotype in breast
cancer cell lines suggest a role for this signal transduction
pathway in the pathogenesis and/or progression of breast
cancer. To examine the role of PKC in the progression of
breast cancer, human MCF-7 breast cancer cells were
transfected with PKC-a, and a group of heterogenous cells
stably overexpressing PKC-a were isolated (MCF-7-PKC-
a). MCF-7-PKC-a cells expressed fivefold higher levels of
PKC-a as compared to parental or vector-transfected MCF-
7 cells. MCF-7-PKC-a cells also displayed a substantial
increase in endogenous expression of PKC-8 and decreases
in expression of the novel 6- and q-PKC isoforms.
MCF-7-PKC-a cells displayed an enhanced prolifera-
tive rate, anchorage-independent growth, dramatic morpho-
logic alterations including loss of an epithelioid appearance,
and increased tumorigenicity in nude mice. MCF-7-PKC-
a cells exhibited a significant reduction in estrogen receptor
expression and decreases in estrogen-dependent gene ex-
pression. These findings suggest that the PKC pathway may
modulate progression of breast cancer to a more aggressive
neoplastic process. (J. Clin. Invest. 1995. 95:1906-1915.)
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Introduction
Protein kinase C (PKC)' is a gene family consisting of several
subfamilies (conventional: a, /3k, 31, y, novel: 6, E, 9, 77; and
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1. Abbreviations used in this paper: CAT, chloramphenicol acetyltrans-
ferase; MDR, multidrug resistant; PKC, protein kinase C; TPA, tetrade-
canoyl-13-phorbol acetate; vit-tk-CAT, estrogen-responsive vitellogenin
promoter-CAT reporter construct.
atypical: X, 4, t) that lie on signal transduction pathways regu-
lating growth and differentiation in a large and diverse group
of cell types ( 1, 2).
A role for members of the PKC gene family in regulating
growth and differentiation of breast cancer has been suggested
by several separate observations. In extracts prepared from sam-
ples derived from patients undergoing breast biopsy, PKC activ-
ity was elevated in malignant breast tumors relative to normal
breast tissue (3). In cultured breast cancer cell lines, a positive
correlation also existed between PKC activity and the more
biologically aggressive estrogen receptor negative phenotype
(4, 5). In the MCF-7 and other breast cancer cell lines, phorbol
ester treatment that induced downregulation of PKC activity
inhibited growth and enhanced expression of parameters associ-
ated with a more differentiated phenotype (6-9). Studies exam-
ining the effects of bryostatin-1 and tetradecanoyl-13-phorbol
acetate (TPA) on growth of breast cancer cell lines have impli-
cated a role for the conventional PKC-a isoform in mediating
TPA-induced growth inhibition (8). Desensitization to phorbol
ester-induced growth inhibition has been associated with in-
creases in PKC content and activity (6). Additionally, inhibitors
of PKC-associated kinase activity, such as the staurosporine
analogue UCN-01, inhibit growth of the MCF-7 cell (10).
These findings suggest that aberrations in the PKC signal trans-
duction pathway may be involved in the pathogenesis and/or
progression of breast cancer, and that PKC may be involved in
the regulation of estrogen receptor expression, a parameter of
prognostic and therapeutic importance.
Given the possible role for the PKC signal transduction
pathway, specifically PKC-a, in the pathogenesis of breast can-
cer, we directly examined the effects of stably overexpressing
PKC-a on the MCF-7 human breast cancer cell line. Stable
overexpression of PKC-a led to an enhanced rate of prolifera-
tion, more efficient anchorage-independent growth, dramatic
alterations in cellular morphology manifested by loss of an
epithelioid appearance with a marked increase in vimentin ex-
pression, a marked decrease in estrogen receptor mRNA tran-
scripts and estrogen-dependent gene expression, enhanced tu-
morigenicity with metastatic capacity when injected into nude
mice, and significant increases in the endogenous expression
of PKC-/3 accompanied by decreases in the content of PKC-77
and -6.
These findings demonstrate that overexpression of PKC-
a, either directly or indirectly, possibly via increases in the
endogenous expression of PKC-,3 or decreases in the 77 or 6
isoforms, leads to the acquisition of a more fully transformed
phenotype in the MCF-7 breast cancer cell, and provide further
evidence for a possible role of the PKC signaling pathway
in the pathogenesis and/or progression of breast cancer and
regulation of estrogen receptor status.
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Methods
Cell culture. MCF-7 cells were purchased from the American Type
Culture Collection (Rockville, MD) and grown in DME supplemented
with 2 mM glutamine, 10 mM Hepes, 10% FCS, 50 U/ml penicillin,
and 50 jig/ml streptomycin. For cell growth experiments, 7.5 X 103
cells/ml were incubated in 24-well plates. Cell viability was assessed
using trypan blue exclusion. Counting of cells was performed using a
Coulter counter (Coulter Corp., Hialeah, FL).
Generation of MCF-7 cells overexpressing PKC-a. Bovine PKC-a
( 1 ) was subcloned into the pSV2M(2)6 plasmid (20 pig) and cotrans-
fected with 2 jtg pMAM-neo plasmid (Clonetech, Palo Alto, CA) by
calcium phosphate precipitation. The pSV2M(2)6 vector was gener-
ously provided by Dr. Marilyn Sleigh (Commonwealth Scientific and
Industrial Research Organization, Sydney, Australia [12]). 72 h after
transfection the cells were incubated in 0.75 mg/ml G418. After a 6-
wk selection period, multiple clones of cells overexpressing PKC-a
(MCF-7-PKC-a) and vector without the PKC insert were detected.
The results presented herein are derived from pooling these separate
clones into heterogeneous groups of vector- or PKC-a-transfected cells.
Although transfected PKC-a is under control of a metallothionein pro-
moter, cells stably transfected with this construct displayed marked
phenotypic changes and overexpressed the a isoform approximately
fivefold in the absence of supplemental heavy metals beyond the quanti-
ties contained in FCS (see Results). Because of the basal induction of
PKC-a, experiments were done in the absence of further heavy metal
supplementation. The MCF-7-PKC-a and vector-transfected cells have
maintained stable phenotypic characteristics over a 9-mo period.
PKC activity and Western blot analysis. Cytosolic, solubilized par-
ticulate, or whole-cell solubilized extracts, were prepared as previously
described (13) and used for quantitation of PKC activity and Western
blot analysis. Protein content was determined by the Bradford technique
(14). Using equal protein concentrations (10 jtg), PKC activity was
assessed as previously described ( 15 ) with histone III-s, a peptide corre-
sponding to residues 4-14 of myelin basic protein (16), and a serine-
substituted PKC-6 pseudosubstrate site peptide ( 15) as substrates. PKC
activity was defined as the difference in cpm incorporated into the
substrates in the absence and presence of TPA and phosphatidylserine.
Western blot analysis was done as previously described using anti-
sera specific for the a, /3, c, and 4 isoforms (13, 15). Antipeptide
antiserum against the carboxy terminus of PKC-77 (INQDEFRNFSYV-
SPELQL) was prepared and used in this study at a dilution of 1:1,000.
This antiserum recognized a protein doublet at approximately the pre-
dicted molecular weight for PKC-77 and a slightly lower molecular
weight species. The specificity of these proteins was confirmed by the
ability of the immunizing peptide to abolish detection of these bands.
A separate PKC-77 antiserum, purchased from Santa Cruz Biotechnol-
ogy, Inc., (Santa Cruz, CA) gave identical results to those obtained
using our 7 antipeptide antibody. Antiserum to PKC-6 was purchased
from Transduction Labs (Lexington, KY) and was used as per their
recommendations. Detection was performed using goat anti-mouse an-
tiserum and enhanced chemiluminescence (15). Densitometric analysis
of the autoradiograms was performed using a laser densitometer (Ul-
trascan XL; Pharmacia LKB Biotechnology, Inc., Piscataway, NJ).
Northern blot analysis. RNA was extracted using a single-step acid
guanidinium thiocyanate-phenol extraction technique (17). RNA (20
jig) was electrophoresed, transferred to nylon filters, and hybridized to
random primer labeled cDNA probes (18). Ethidium bromide staining
was used to confirm the integrity of the RNA and assess the equivalency
of loading. The probes used for PKC-fl, -77, and -6 were isolated by P.
Parker and represent the full length cDNAs. The vimentin cDNA was
generously provided by Dr. Susan Rittling (Rutgers University). Probes
for the estrogen receptor, cathepsin D, and pS2 genes were purchased
from the American Type Culture Collection.
Microscopy. Cells maintained in culture were photographed at a
magnification of 400 with an inverted microscope (Diaphot; Nikon,
Inc., Melville, NY). For structural analysis, cells were fixed for 30 min
in 2.5% (vol/vol) glutaraldehyde and 0.2 M phosphate buffer (pH
7.4). After postfixation in 1% (wt/vol) osmium tetroxide, cells were
dehydrated through a graded series of alcohol and propylene oxide and
embedded in Epon (Electron Microscopy Sciences, Fort Washington,
PA). Thin sections (< 90 nm) were stained with uranyl acetate and
lead citrate and examined with an electron microscope ( 1200 EX; JEOL
USA Inc., Peabody, MA).
Cell cycle analysis. 30 min before harvesting, cells were incubated
with 10 ,M bromodeoxyuridine. Cells were then trypsinized, washed,
resuspended in PBS, and fixed in 70% ethanol at 40C for 30 min. The
fixed cells were treated at room temperature for 6 min with 6 N HCL
containing 0.5% Triton X-100. After washing with PBS, the cells were
resuspended in serum-free RPMI 1640 media and incubated for 15
min at room temperature with FITC-conjugated antibromodeoxyuridine
antiserum (Becton Dickinson Immunocytometry Systems, Mountain
View, CA). The samples were washed, resuspended in 50 jug/ml propid-
ium iodide contained in a citrate buffer, and immediately analyzed on
a flow cytometer (Facscan®; Becton Dickinson Immunocytometry Sys-
tems). Linear red and green fluorescence and logarithmic forward and
side scatter signals were obtained on 104 cells. For statistical analysis,
polygonal regions were drawn on a propidium iodide versus bromodeox-
yuridine 2-parameter histogram display defining cells in GO/GI, S, and
G2M phases. The percentage of cells falling within these regions was
calculated using the Facscan® statistical analysis package (Becton Dick-
inson Immunocytometry Systems) and normalized to 100%.
Transfection and reporter construct analysis. Cells were transiently
transfected using calcium phosphate precipitation with 3 Isg p-cytomeg-
alovirus /3-galactosidase plasmid (Clonetech Laboratories, Palo Alto,
CA), 4 ,g estrogen-responsive vitellogenin promoter-chloramphenicol
acetyltransferase reporter construct (vit-tk-CAT), and 13 ig of carrier
DNA. After an overnight incubation, the cells were washed and grown
in media with 10% FCS. 40 h later, fi-galactosidase and CAT activity
were analyzed by standard methodologies and CAT measurements were
normalized to ,6-galactosidase activity. The estrogen-responsive, vit-tk-
CAT construct was kindly provided by Dr. Gerhardt Ryffel (Kern-
forschungszentrum, Karlsruhe Institut fur Genetik und Toxikolo-
gie [19]).
Growth in soft agar. In a 35-mm dish, 1 ml of 0.6% agar in DME
with 10% FCS was plated and allowed to harden. Top agar, 0.36%,
containing 103 cells/ml was layered over the hardened agar. Cultures
were incubated at 37° C in 5% CO2 for 10-12 d. Colonies > 50 cells
were visually enumerated.
Tumor and metastatic evaluation in nude mice. BALB/c nu/nu
female mice, 6-8 wk old, were inoculated with 7 x 106 cells in 0.1
ml of PBS into the mammary fat pad. Because of the rapid primary
tumor growth in mice inoculated with the MCF-7-PKC-a cells, animals
were killed only 4 wk after inoculation. Tumor volume was assessed
by measuring tumor size in three dimensions. Histologic examination
of the primary tumor and other organs was done using hematoxylin and
eosin staining.
Results
Overexpressing of PKC-a increased PKC activity and altered
expression of endogenous PKC isofonns. MCF-7 cells were
cotransfected with the neomycin resistance plasmid and either
the pSV2M(2)6 vector without the insert or containing a full-
length cDNA encoding PKC-a. Cells harboring the neomycin
resistance gene were identified by selection in G418. Rather
than single cell cloning, a mixed group of neomycin-resistant
cells was isolated. A heterogenous population of transfected
cells was used to minimize the possible artifacts that can be
associated with single cell cloning. Analysis of PKC-a expres-
sion is shown in Fig. 1. As compared to either parental MCF-
7 cells or cells stably transfected with the neomycin gene and
vector without the PKC insert, PKC-a was overexpressed ap-
proximately three- to fivefold, as assessed by densitometric
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Figure 1. PKC-a content, and PKC activity in MCF-7-PKC-a. Equal
amounts of protein (40 [tg) derived from cytosolic (C) and solubilized
particulate (P) fractions from parental (con) and MCF-7-PKC-a
(PKC-a) cells were subjected to Western blot analysis using PKC-a
antiserum (inset). PKC activity of the same cells is shown below. The
substrates used are indicated beneath the figure. PKC activity is defined
as the difference in cpm incorporated into substrate in the absence and
presence of phosphatidylserine and TPA in parental (con) and MCF-
7-PKC-a (a) cells. These experiments were repeated on three separate
occasions with similar results.
analysis, in the cells stably transfected with this isoform (MCF-
7-PKC-a cells). Corroborating the increased content of this
isoform in PKC-a cells was a 5-16-fold increase, depending
upon the substrate used, in PKC activity in the MCF-7-PKC-
a cells as compared to the parental MCF-7 cell (Fig. 1).
Endogenous expression of other PKC isoforms in MCF-7-
PKC-a cells was examined by Western blot analysis (Fig. 2
A). Parental MCF-7 cells contained readily apparent amounts
of a, E, 6, and 4 isoforms (Figs. 1 and 2). Using a antiserum
directed against the V3 region of the molecule, we were unable
to detect significant PKC-,/ expression in the parental MCF-7
cell. The PKC-r7 antiserum specifically detected three bands
with molecular weights of 86, 82, and 60 kD. Relative to the
parental MCF-7 cells, MCF-7-PKC-a cells displayed a large
increase in protein content of 6 and similar quantities of c and
4. Levels of 6 were reduced modestly in MCF-7-PKC-a cells.
Levels of the 86- and 82-kD proteins detected by the PKC-i7
antiserum were negligible in MCF-7-PKC-a cells. Content of
the lower 60-kD protein detected by the 7 antiserum was also
substantially reduced in MCF-7-PKC-a cells. The identity of
the 60-kD protein and its relation to the predicted molecular
weight form of remains unresolved. Densitometric scanning
of cytosolic and solubilized particulate fractions subjected to
Western blot analysis indicated the following subcellular distri-
bution of PKC isoforms in MCF-7 cells: a, 65/35 (percentage
of total isoform content in cytosolic/solubilized particulate frac-
tions); c, 60/40; 4, 52/48; r 86-kD species, 39/61; i1 82-kD
species, 53/47; and rq 60-kD species, 80/20. In MCF-7-PKC-a
cells, the cytosolic/solubilized particulate fraction distributions
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Figure 2. Altered endog-
enous PKC isoform con-
tent in MCF-7-PKC-a
cells. (A) Western blot
analysis was performed
on equal protein concen-
trations of whole-cell
solubilized fractions de-
rived from parental and
UC V C MCF-7-PKC-a cells.The antisera used are in-
dicated (left). Molecular
weight standards are
shown to the left of the
;... PKC-r1 autoradiogram.
Vector-transfected cells
V;k'M displayed identical PKC
isoform expression as did
parental MCF-7 cells.
(B) Northern blot analy-: * ,s using total RNA (20
MIF-g)prepared from pa-rental (C), vector (V),
and MCF-7-PKC-a (a)
cells was performed with
PKC-,8, -r7, and -6 DNA
probes. The approximate
molecular weight of the
detected mRNA tran-
scripts is indicated to the
side of the autoradio-
gram. Ethidium bromide
(EtBr) staining is shown
below the autoradio-
grams. These experi-
ments were performed on
a separate occasions with
similar results.
were as follows: a, 46/54; /3, 81/19; E, 56/44; ;, 58/42; and
r1 60-kD species, 60/40. Because of their negligible amounts,
PKC-,/ and the 86/82-kD species of PKC-r1 could not be quanti-
tated in MCF-7 and MCF-7-PKC-a cells, respectively. Be-
cause of these changes in the endogenous expression of the /,
6, and isoforms in MCF-7-PKC-a cells, Northern blot analy-
sis was performed to examine the content of their mRNA tran-
scripts. A concomitant increase in mRNA transcripts for the
isoform and decreases in the 6 and rq isoform mRNA transcripts
were noted in the MCF-7-PKC-a cells (Fig. 2 B). Thus, either
in a direct fashion or secondary to the phenotypic changes dem-
onstrated in MCF-7-PKC-a cells (see below), PKC-a overex-
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Figure 3. Dissimilar morphology of MCF-7-PKC-a and parental MCF-7 cells. Exponentially growing parental (A), vector-transfected (B), and
MCF-7-PKC-a (C) cells were photographed at a magnification of 400 using a Diaphot inverted microscope.
pression modulated expression of other endogenous PKC family
members.
Overexpression of PKC-a drastically altered morphology of
the MCF-7 cell. MCF-7-PKC-a cells demonstrated dramatic
morphologic alterations as compared to parental MCF-7 cells
(Fig. 3). Parental and vector-transfected MCF-7 cells displayed
an epithelioid appearance growing adherent to the plastic surface
(Fig. 3, A and B, respectively). In marked contrast, MCF-7-
PKC-a cells assumed a spherical shape, could proliferate in sus-
pension, especially as cell density increased, and occasionally
formed giant cells (Fig. 3 C). Electron microscopy indicated that
parental MCF-7 cells contained primary lysosomal granules (Fig.
4 A, black triangular indicators), while MCF-7-PKC-a cells
contained an abundance of secondary lysosomal granules (Fig.
4 B, thin arrows). The nuclear to cytoplasmic ratio was signifi-
cantly greater in MCF-7-PKC-a cells. While not observed in
MCF-7 cells, areas enriched in intracellular fibrils were noted in
MCF-7-PKC-a cells (Fig. 4 X, thick arrows). At a magnifica-
tion of 50,000 these fibrils had a diameter consistent with interme-
diate filaments (data not shown). As shown in Fig. 4 C, Northern
blot analysis revealed a dramatic increase in mRNA transcripts
for vimentin, an intermediate filament that is not normally ex-
pressed in MCF-7 cells (20) and whose expression is a poor
prognostic indicator in breast cancer (21, 22).
MCF-7-PKC-a cells are estrogen receptor negative and
display a loss ofestrogen-dependent gene expression. In previous
studies an association between increases in PKC activity and
decreases in estrogen receptor expression have been noted (4, 5).
Given this association and the more morphologically aggressive
appearance of the MCF-7-PKC-a cell, estrogen receptor status
was analyzed (Fig. 5 A). By Northern blot analysis, parental
MCF-7 cells were shown to contain transcripts for estrogen recep-
tor mRNA. In contrast, mRNA transcripts for the estrogen recep-
tor were not detected in MCF-7-PKC-a cells. To assess the
functional importance of this finding, expression of estrogen-
responsive genes and the activity of an estrogen-responsive genes
and the activity of an estrogen-responsive reporter construct were
analyzed. Expression of estrogen-responsive genes, pS2, and ca-
thepsin D (23, 24), were markedly decreased in MCF-7-PKC-
a cells grown in the presence of 10% FCS (Fig. 5 A). Activity
of the estrogen-responsive vit-tk-CAT reporter construct in-
duced by estrogens contained in 10% FCS was apparent in paren-
tal MCF-7 cells (Fig. 5 B). However, this estrogen-dependent
activity was minimal in MCF-7-PKC-a cells. Thus, the MCF-
7-PKC-a cells share a similar relationship between decreased
estrogen receptor expression and increased PKC activity, as has
previously been described in clinical samples from patients with
breast cancer (4).
MCF-7-PKC-a cells demonstrate a higher proliferative
rate and enhanced anchorage-independent growth. MCF-7-
PKC-a cells proliferated at a higher rate than did parental or
vector-transfected cells (Fig. 6 A). As MCF-7-PKC-a in-
creased in density, they detached from the plastic surface and
proliferated in suspension (Fig. 6 B). The nonadherent popula-
tion of the MCF-7-PKC-a were viable as assessed by trypan
blue exclusion (data not shown). In contrast, parental MCF-7
cells proliferated in an adherent fashion (Fig. 6 B). MCF-7-
PKC-a and parental or vector-transfected cells reached satura-
tion density at 1.2 x 106/ml and 0.5 X 106/ml, respectively
(data not shown). The importance of the higher cell density at
confluence in MCF-7-PKC-a cells is somewhat uncertain
given the ability of these cells, but not the parental MCF-7
cells, to grow in suspension.
Given the rapid proliferative rate of MCF-7-PKC-a cells
and the poor prognostic value in clinical specimens of a high
S phase value (25), the proportion of exponentially growing
cells in S phase was evaluated. In parental MCF-7 cells, the
cells were proportioned as follows: Go/GI: 61± 1.6; S: 23±1.3;
and G2/M: 16±1.5 (X±SEM, n = 10). In MCF-7-PKC-a
cells, the cell cycle distribution was as follows: GO/GI: 44±1.2;
S: 39+2.4; and G2/M: 17±1.5 (X±SEM, n = 8). Thus, MCF-
7-PKC-a cells displayed an increase in S phase cells with a
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concomitant decrease of cells in Go/G1. Using a two-tailed
Student's t test, these differences between the parental MCF-7
and MCF-7-PKC-a cells were statistically significant at a level
of <0.05.
MCF-7-PKC-a cells readily grew in an anchorage-indepen-
dent manner in soft agar (Fig. 7). However, under these experi-
mental conditions, parental MCF-7 cells displayed negligible
anchorage-independent growth with only a few cell clusters
observed and no colonies of > 50 cells detected (Fig. 7).
MCF-7-PKC-a cells were tumorigenic in nude mice with
a propensity to metastasize. When injected into the mammary
fat pad, MCF-7-PKC-a cells rapidly formed large primary tu-
mors in all mice by 4 wk postinoculation (Table I). The single
mouse that did not form a tumor when inoculated with MCF-
7-PKC-a cells was inadvertently injected outside the mammary
fat pad and into the subcutaneous space. The tumors in mice
inoculated with MCF-7-PKC-a cells were well circumscribed
and bordered by a thin fibrous tissue network. Histologically,
the MCF-7-PKC-a primary tumors were composed of solid
sheets of tightly packed, anaplastic, round to polygonal cells
with scant basophilic to pale eosinophilic cytoplasm and mild
cellular pleomorphism (Fig. 8, A and B). Marked nuclear pleo-
morphism, increased content of nucleoli, and numerous mitotic
figures were also noted in the primary MCF-7-PKC-a tumors.
In contrast, parental MCF-7 cells formed only microscopic,
Figure 4. Electron microscopy of MCF-7 and
MCF-7-PKC-a cells. Electron microscopy
was performed on parental MCF-7 (A) and
MCF-7-PKC-a (B) cells at x5,000. In A,
the black triangular indicators mark primary
lysosomal granules. In B, the thin arrows
point to secondary lysosomal granules while
the thicker arrows are directed at a bundles
of intracellular fibrils. Northern blot analysis
of vimentin expression in parental MCF-7
and MCF-7-PKC-a cells is shown in C.
Ethidium bromide staining demonstrated that
equivalent amounts of RNA were loaded per
lane (data not shown).
nonpalpable primary tumors in 2/10 animals with no detectable
metastases. Western blot analysis of the primary MCF-7-PKC-
a tumors demonstrated the continued expression of a, A, 6, E,
77, and 4 isoforms (data not shown). Due to the microscopic
size of the tumors in mice injected with parental MCF-7 cells,
a direct comparison between the relative in vivo expression of
isoforms in parental MCF-7 and MCF-7-PKC-a cells could
not be made. In mice inoculated with MCF-7-PKC-a cells,
metastases were observed in lymph nodes, lung, and perinephric
fat (Table I). Metastases in mice inoculated with MCF-7-PKC-
a cells were microscopic in size. The full extent of the meta-
static potential of the MCF-7-PKC-a cell may have been un-
derestimated because of the relatively short period from inocula-
tion to necropsy (4 wk) that was necessitated by the rapid
growth of the primary MCF-7-PKC-a tumor. Given the posi-
tive correlation between metastatic capacity and the size of the
primary breast tumor (26), it is uncertain whether MCF-7-
PKC-a cells had a higher metastatic potential simply because
of their high growth rate or whether these cells acquired separate
biologic programs, rendering them with an intrinsically in-
creased metastatic capacity.
Discussion
This study demonstrates that human MCF-7 breast cancer cells
transfected with and overexpressing PKC-a display enhanced
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Figure 5. Diminished estrogen receptor content and function in MCF-
7-PKC-a cells. (A) Total RNA, 20 .g, prepared from parental and
MCF-7-PKC-a cells, was subjected to Northern blot analysis using
cDNA probes corresponding to the estrogen receptor (ER), pS2, and
cathepsin D as shown to the left of the autoradiograms. Equivalent
amounts of RNA were loaded per lane as assessed by ethidium bromide
staining (data not shown). (B) vit-tk-CAT activity normalized to f3-
galactosidase measurements (ordinate) was analyzed in parental and
MCF-7-PKC-a cells transiently transfected with this reporter construct.
The bars represent SEM. Each of these experiments was repeated with
similar results.
growth rate with a higher percentage of cells in S phase, anchor-
age-independent proliferation, a transition from an epithelial
to a mesenchymal-like morphology, loss of estrogen receptor
content, and increased tumor formation with metastatic capacity
in nude mice. The transition to a more mesenchymal appear-
ance, the corresponding increase in vimentin expression, a high
S phase fraction, and the loss of estrogen receptor expression
with the attendant decrease in levels of the pS2 mRNA tran-
scripts occurring in the MCF-7-PKC-a cell are observed in
breast cancer patients with a more malignant course and less
favorable prognosis (21-23, 27, 28). Interestingly, mRNA
transcripts for cathepsin D were markedly reduced in the MCF-
7-PKC-a cell. While cathepsin D is an estrogen-responsive
gene, clinical studies have demonstrated that cathepsin D ex-
pression is a poor prognostic indicator, with high levels pre-
dicting a poor clinical outcome in breast cancer patients (29).
Thus, the reduced cathepsin D content in MCF-7-PKC-a cells
seems at odds with the obvious progression of this cell to a
more aggressive phenotype. Perhaps explaining this discrepancy
is the finding that in clinical specimens the cathepsin D content
may be derived from cells other than mammary epithelium cells
(30). Thus, the MCF-7-PKC-a cell seems to recapitulate a
very similar phenotype to that found in more aggressive lesions
derived from patients with breast cancer. This close recapitula-
tion of phenotypic characteristics substantiates a possible role
for alterations in the PKC pathway in modulating the in vivo
progression of human breast cancer and suggests the potential
usefulness of the MCF-7-PKC-a cell in screening antineoplas-
tic agents used for treating advanced forms of breast cancer.
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Figure 6. MCF-7-PKC-a cells exhibit a higher proliferative rate than
MCF-7 cells. (A) MCF-7 (o0o), vector-transfected (.-*), and
MCF-7-PKC-a (A-A) cells were plated in 24-well plates at 7.5
x 103/ml, and total cell number was assessed at various times (abscissa)
after plating. (B) In a separate experiment, the growth of nonadherent
MCF-7 (o0o) and MCF-7-PKC-a (A - - A) cells is shown. The num-
ber of nonadherent cells is expressed as a percentage of total cells. Each
point is derived from six separate samples. These experiments were
repeated on several occasions with similar results.
A negative correlation between PKC activity and estrogen
receptor status in breast cancer has been previously noted (4,
5). The mechanism responsible for this association has yet to
be fully elucidated. Exposure of breast cancer cells to phorbol
esters that both activate and downregulate PKC activity results
in a significant reduction in mRNA transcripts of the estrogen
receptor (30-32). Given that the status of alterations within
the PKC pathway was not evaluated in these investigations (31-
33), the specific mechanism by which phorbol esters interacted
with the PKC pathway to decrease the level of mRNA tran-
scripts for the estrogen receptor gene is unclear. Thus, estrogen
receptor expression could be negatively modulated by phorbol
ester-induced activation of a specific PKC isoform(s) or be-
cause of downregulation of an isoform( s) necessary for mainte-
nance of estrogen receptor mRNA levels. In the MCF-7-PKC-
a cell, the predominant alterations in the PKC pathway were
an increase in the conventional a and isoforms. It is tempting
to speculate that the increased content of these isoforms led
directly to an enhanced basal kinase activity, which in turn
activated a cascade that decreased content of estrogen receptor
mRNA transcripts. Given the increased level of PKC-a in the
estrogen receptor-negative MCF-7-PKC-a cell and the in-
creased PKC-a levels with a reduction in PKC-,B content in the
estrogen receptor-negative, multidrug-resistant (MDR) MCF-
7-MDR cells (33), a role for PKC-a in negatively modulating
estrogen receptor expression seems possible. Obviously, further
studies will need to be undertaken to prove such a hypothesis.
The significant morphologic alterations and higher degree
of phenotypic transformation observed in the MCF-7-PKC-a
cell contrast with the MCF-7-MDR clones that also overex-
press PKC-a. In the MCF-7-MDR subclones, PKC-a overex-
pression, relative to parental MCF-7 cells, is at least as much
as or greater than that seen in MCF-7-PKC-a cells (34). The
lack of similar morphologic and proliferative alterations in
MCF-7-MDR cells suggests that PKC-a may not be directly
responsible for the entirety of the changes observed in the MCF-
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Cells: Vector MCF-7-PKCca
Colonies: 0 227 ± 8.9
( +±SEM)
Figure 7. Anchorage-independent growth of MCF-7-PKC-a cells. Growth in soft agar of vector-transfected and MCF-7-PKC-a cells was performed
as described in Methods. A colony was defined as a group of > 50 cells. Colony growth is expressed as X +SEM, n = 4. This experiment was
repeated with similar results.
7-PKC-a cells. Possibly explaining this discrepancy are differ-
ences in expression of other PKC isoforms in the MCF-7-PKC-
a and MCF-7-MDR cells. In MCF-7-MDR cells, PKC-e is
undetectable and significant decreases in the /3 and 6 isoforms
are detected (34). In contrast, PKC-/3 expression is enhanced,
levels of PKC-6 are only modestly decreased, and PKC-e con-
tent is unchanged in MCF-7-PKC-a cells. In addition, content
of PKC-iq is markedly decreased in MCF-7-PKC-a cells, and
to our knowledge the status of this isoform in MCF-7-MDR
has not yet been reported. The decreased PKC-27 content in
MCF-7-PKC-a cells. may be related to the less differentiated
status of this breast epithelial cell. In other epithelial cell types,
a positive correlation exists between the level of PKC-77 expres-
sion and a more differentiated epithelial phenotype (35). Thus,
the dissimilar phenotypes displayed by MCF-7-PKC-a and
MCF-7-MDR cells could result from the differences in the
array of expression of other PKC isoforms or an interplay be-
tween the content of an individual PKC isoform or subfamily
relative to that of another isoform or subfamily. Alternatively,
other phenotypic alterations occurring in the MCF-7-MDR cell
resulting from selection in doxorubicin could modify the re-
sponse of this cell to the elevated levels of PKC-a. This latter
possibility is suggested by the finding that overexpression of
PKC-a in an MCF-7 cell line that was clonally isolated on the
basis of its resistance to doxorubicin was reported to proliferate
at approximately the same rate as the parental MCF-7 cell (36).
An alternative explanation for the different phenotype ex-
pressed by the MCF-7-PKC-a cell is that exposure to G418
Table L Tumorigenicity of MCF- 7 and MCF- 7-PKC-a Cells in Nude Mice
Site of metastasis
Animals with Volume of primary Number of animals Lymph Perinephric
Inoculated cell type primary tumor tumor with metastasis Lung nodes fat
MCF-7 2/10* < 1 m3 0/10 0/10 0/10 0/10
MCF-7-PKC-a 9/10t 3,383 mm3±937' 6/1011 4/101 2/7 3/10
* Animals having either micro- or macroscopic primary tumors at 4 wk after inoculation with 107 cells. * The animal not exhibiting a primary
tumor had cells inadvertently injected into the subcutaneous space. I X±SEM; n = 9; range: 630-7,344 mm3; vol was defined as the product of
length x width x diameter in mm. 11 In one mouse, the contiguous muscle was extensively invaded by the primary tumor. 1 Metastases at all sites
were microscopic in size. A denominator less than the 10 animals in each group indicated that the specific anatomic site was not examined in all
animals.
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Figure 8. Histologic appearance of primary and metastatic lesions in nude mice. The primary tumors derived from mice injected with 7 x 106
parental MCF-7 and MCF-7-PKC-a cells for 4 wk are shown in A and B, respectively.
resulted in selection of a neomycin-resistant cell with dramati-
cally altered phenotypic characteristics that fortuitously overex-
pressed PKC-a. While it is impossible to totally exclude this
possibility, we believe that this scenario is unlikely. In mock
or vector-transfected MCF-7 cells, we have not observed the
selection of a cell with a MCF-7-PKC-a-like phenotype. All
G418-resistant cells from MCF-7 cells transfected with the neo-
mycin resistance gene display an epithelioid appearance and
have proliferative characteristics similar to parental MCF-7
cells. To our knowledge, examples of epithelial cells selected
in G418 exhibiting MCF-7-PKC-a-like phenotypic character-
istics and concomitantly overexpressing PKC-a have not been
reported. Thus, we believe that the phenotypic alterations oc-
curring in the MCF-7-PKC-a cell were initiated by and are
related to overexpression of PKC-a.
While enhancing tumorigenicity in breast cancer cells, PKC-
a overexpression in murine fibroblasts and R6 cells inhibits
proliferation and does not lead to transformation (37, 38). In
hematopoietic cells, increases in the endogenous expression of
PKC-a are associated with differentiation and cessation of
growth (13). These divergent effects indicate that alterations
in proliferation or differentiation induced by PKC-a overex-
pression are not an intrinsic property of this isoform, but are
modulated by a dynamic interaction between cell-specific and
maturationally related factors.
The mechanism by which overexpression of PKC-a alters
morphology, enhances proliferation, increases tumorigenicity,
and enhances metastatic potential remains to be determined.
The increased mass of PKC-a would be predicted to increase
the basal level of kinase activation. An enhanced basal level of
kinase activation leading to increased phosphorylation of cellu-
lar substrates could induce the phenotype observed in the MCF-
7-PKC-a cells. However, activation of PKC-a and other en-
dogenous MCF-7 isoforms in the parental MCF-7 cell by either
TPA or cell permeant diacylglycerol derivatives causes growth
inhibition and differentiation (6-9). Thus, if an increase in the
basal kinase activity was responsible for the observed changes
in the MCF-7-PKC-a cell, then qualitatively different cellular
responses are elicited by PKC-associated kinase activity stimu-
lated by autocrine mechanisms or factors contained in serum
(e.g., enhanced proliferation in MCF-7-PKC-a cells). Alterna-
tively, PKC-a overexpression may use a kinase-independent
mechanism to elicit the phenotypic alterations observed in the
MCF-7-PKC-a cell. A kinase-independent mechanism is sup-
ported by the temporal association of an increase in an under-
phosphorylated, kinase-inactive species of PKC-a in TPA-
treated MCF-7 cells that have become desensitized to TPA-
induced growth inhibition and have resumed proliferation (6).
Therefore, PKC-a overexpression, whether via direct protein-
protein interactions or through a potential association with DNA
by the cysteine-rich zinc fingers contained in the C1 domain,
has the theoretical potential to elicit signal transduction by a
kinase-independent mechanism. Further studies with kinase-de-
fective PKC-a mutants will be required to directly assess this
hypothesis. Lastly, the phenotypic alterations in MCF-7-PKC-
a cells could be due in part to the high level of PKC-#B expres-
sion or reduction in PKC-77 and -6 content. Given the low level
of #3 expression in the parental cell, the signal transmitted by
phorbol ester-induced activation of this isoform would be lim-
ited relative to that elicited by stimulation of the other TPA-
responsive isoforms (a, 6, 71, and e). Thus, the biologic re-
sponses in TPA-treated parental MCF-7 cells would largely
reflect activation of the a, 6, rq, and e isoforms. In MCF-7-
PKC-a cells, PKC-,/ is highly overexpressed and would be
predicted to contribute substantially to the basal level of kinase
activity generated by PKC family members, while the contribu-
tion from PKC-r1 and -6 would be less. As has been postulated
by others ( 1, 2), differences in substrate specificity or subcellu-
lar distribution of PKC-,/ could elicit qualitatively dissimilar
cellular responses from those induced by the a, 6, i7, and E
isoforms. Such differences between isoforms and the high de-
gree of, overexpression with the concomitant reduction in r,
and 6 expression in MCF-7-PKC-a cells could provide a possi-
ble mechanism explaining the divergent growth and phenotypic
characteristics of parental MCF-7 and MCF-7-PKC-a cells.
The anchorage-independent growth of MCF-7-PKC-a cells
demonstrates that anoikis that normally occurs upon detachment
of epithelial cells from their matrix has been abrogated (39).
A role for the PKC pathway in negatively modulating initiation
of anoikis has been previously demonstrated in phorbol ester-
treated Madin-Darby canine kidney epithelial cells (39). Our
results extend this observation regarding the inhibitory effects
of the PKC pathway on induction of anoikis to mammary epithe-
lial cells and suggest a potential role for the conventional PKC
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isoforms in regulating this process and its clinical counterpart,
metastasis.
Expression of PKC-/3 was enhanced in the MCF-7-PKC-
a cell. The human PKC-f promoter contains multiple enhancer
elements, including AP-1, AP-2, SpI, E box, and octamer mo-
tifs, and also contains a sequence involved in transcriptional
silencing (40). Interestingly, in K562 erythroleukemia cells,
both basal and TPA-inducible expression of PKC-,6 only require
a sequence containing two SpI sites, an E box, and an octamer
motif (40). Given that the AP-1 and AP-2 sites are not neces-
sary for induction of this gene, it has been postulated that tran-
scriptional activation occurs via a non-AP-1-dependent mecha-
nism (40). Consistent with these results, our findings show that
TPA treatment for a 24-h period does not increase expression
of PKC-/3 mRNA transcripts in parental MCF-7 cells (data not
shown). These findings suggest that, in MCF-7-PKC-a cells,
induction of PKC-,6 expression occurs either as a direct effect
of PKC-a overexpression by a kinase-independent mechanism
or secondary to phenotypic changes associated with the MCF-
7-PKC-a cell. The factors, and the level at which they act to
modulate the endogenous expression of the ,f isoform, are under
investigation in our laboratories.
The clinical significance of these findings in the prognostic
evaluation of malignant breast lesions and in developing novel
therapeutic modalities seems promising. Assessing the level and
array of specific PKC isoform expression in primary breast
masses could be useful in gauging the metastatic potential and/
or biological aggressiveness of the lesion. Such information
could be of use in determining the appropriate degree of radia-
tion or chemotherapeutic intervention, especially in circum-
stances such as axillary node-negative disease. The ability of
PKC-a overexpression to enhance proliferation and to induce
a more biologically aggressive phenotype, either directly or
indirectly via alterations in expression of other endogenous PKC
isoforms, also indicates the potential promise of therapeutic
modalities directed at inhibiting isoform(s) expression or func-
tion. Currently, such methodology is available using antisense
or ribozyme therapy directed against individual PKC isoforms
or by downregulating PKCs with bryostatin-1 treatment (41,
42). Thus, these findings open exciting new possibilities that
could improve the evaluation and treatment of patients with
certain forms of breast cancer.
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